Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial. The benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.